Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-MSLN CAR-T cells LCAR-M23

A preparation of Tl ymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the human tumor-associated antigen (TAA) mesothelin (MSLN), with potential immunomodulating and antineoplastic activities. Upon administration, the anti-MSLN CAR-T cells LCAR-M23 specifically target and kill MSLN-expressing tumor cells. Mesothelin, a cell surface glycoprotein involved in cell adhesion, is overexpressed in a variety of cancer cell types.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	anti-mesothelin CAR T cells LCAR-M23 mesothelin-targeting CAR T cells LCAR-M23
Code name:	LCAR M23 LCAR-M23 LCARM23

anti-MSLN CAR-T cells LCAR-M23

Search NCI's Drug Dictionary